Nekoee H, Graulich E, Schleich F, et al. Are type-2 biomarkers of any help in asthma diagnosis? ERJ Open Res 2020; 6: 00169–2020.
Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35: 1175e9.
Schleich F, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ⩾3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039–1044.
Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583–593.
Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154: 573–582. Erratum in: Ann Intern Med. 2019; 171: 528.
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–984.
Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–2466.
Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
Schleich F, Graff S, Nekoee H, et al. Real-word experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy 2020; 50: 687–695.
Hekking PP, Zhang K, Garrido CPV, et al. Sputum cytokines associated with raised FENO after anti-IL5 biologic therapy in severe asthma. Allergy 2024; 79: 2244–2247.
Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med 2018; 197: 38–46.
Couillard S, Pavord ID, Heaney LG, et al. Sub-stratification of type-2 high airway disease for therapeutic decision-making: A ’bomb’ (blood eosinophils) meets ’magnet’ (FENO) framework. Respirology 2022; 27: 573–577.
Schleich F, Moermans C, Seidel L, et al. Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction-PROMISE. ERJ Open Res 2023; 9: 00383-2023.
Mukherjee M, Huang C, Venegas-Garrido C, et al. benralizumab normalizes sputum eosinophilia in severe asthma uncontrolled by anti-IL-5 antibodies: a single-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2023; 208: 1330–1335.
Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008; 38: 936–946.
Svenningsen S, Kjarsgaard M, Zhang K, et al. Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma. Allergy 2024; 79: 509–513.
Sabbe M, Schleich F, Janssens P, et al. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic question the role of eosinophils in mediating the clinical expression of the disease: a case report. J Med Case Rep 2024; 18: 63.
